Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_4
4
67%
Ph phase_2
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 44 (66.7%)

Trials by Status

terminated233%
withdrawn117%
completed350%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_4

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

NCT00643604
withdrawnphase_2

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
completedphase_3

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

NCT01416636
completedphase_4

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

NCT00058929
completedphase_4

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

NCT00373360
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00643604Phase 4

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Terminated
NCT01884038Phase 2

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Withdrawn
NCT01416636Phase 3

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

Completed
NCT00058929Phase 4

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Completed
NCT00373360Phase 4

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Completed
NCT00458042Phase 4

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6